Salute e Benessere

Press Release: ESMO: AlphaMedixTM phase 2 data support first-in-class potential…

ESMO: AlphaMedix TMphase 2 data support first-in-class potential of new targeted alpha therapy in gastroenteropancreatic neuroendocrine tumorsNew AlphaMedix data showed sustained and clinically meaningful responses across both RLT-naïve and RLT-exposed patients with unresectable or metastatic GEP-NETs First phase 2 study to evaluate TAT with lead-212 supporting its potential to address high unmet medical needs in difficult-to-treat, rare cancersPhase 2 study met all primary...
Nasdaq GlobeNewswire
20/10/2025

Press Release: ESMO: AlphaMedixTM phase 2 data support first-in-class potential…

ESMO: AlphaMedix TMphase 2 data support first-in-class potential of new targeted alpha therapy in gastroenteropancreatic neuroendocrine tumors New AlphaMedix data showed sustained and clinically meaningful responses across both RLT-naïve and RLT-exposed patients with unresectable or metastatic GEP-NETs First phase 2 study to evaluate TAT with lead-212 supporting its potential to address high unmet medical needs in difficult-to-treat, rare cancersPhase 2 study met...
Nasdaq GlobeNewswire
20/10/2025

Accord Plasma B.V. Expands Global Plasma Therapy Capabilities with Acquisition…

Prothya Biosolutions is one of Europe's leading plasma fractionators, operating major facilities in Amsterdam and Brussels, along with plasma collection centres across Hungary. The company employs approximately 1,200 skilled professionals. Prothya Biosolutions is one ofEurope'sleading plasma fractionators, operating major facilities inAmsterdamandBrussels, along with plasma collection centres acrossHungary. The company employs approximately 1,200 skilled professionals. ...
PR Newswire
20/10/2025

Roche’s Tecentriq showed significant overall and disease-free survival benefits…

Tecentriq reduced the risk of death by 41% and the risk of disease recurrence or death by 36% compared with placebo 1 IMvigor011 is the first global phase III study to read out pioneering a ctDNA- guided approach to post-surgery treatment in muscle-invasive bladder cancerData being presented as part of the Presidential Symposium at the ESMO Congress 2025 Basel, 20 October 2025 - Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today positive results from the phase III IMvigor011...
Nasdaq GlobeNewswire
20/10/2025

FDA approves Roche’s Gazyva/Gazyvaro for the treatment of lupus nephritis

FDA approval based on superiority of Gazyva/Gazyvaro over standard therapy alone, as shown in phase II NOBILITY and phase III REGENCY data 1,2 Gazyva/Gazyvaro is the only anti-CD20 monoclonal antibody to demonstrate a complete renal response benefit in lupus nephritis in a randomised phase III study 2 Lupus nephritis affects more than 1.7 million people worldwide, predominantly women of colour and childbearing age, with up to one-third of patients progressing to end-stage kidney...
Nasdaq GlobeNewswire
20/10/2025

Press Release: Sanofi’s high-dose influenza vaccine demonstrates superior…

Sanofi’s high-dose influenza vaccine demonstrates superior protection for older adults against hospitalization vs standard-dose Compared to standard-dose influenza vaccines, Efluelda/Fluzone High-Dose demonstrated a reduction in laboratory-confirmed influenza hospitalizations by an additional 31.9% (95% CI, 19.7 to 42.2; p<0.001) in adults 65 years and overResults come from FLUNITY-HD, the largest influenza vaccine effectiveness study of individually randomized older adults,...
Nasdaq GlobeNewswire
20/10/2025

Sobi announces revised full year outlook and advances publication of the Q3 2025…

Group Outlook 2025 Group Outlook 2025 At the publication of the Q4 2024 report on5 February 2025Sobi stated the outlook for the FY 2025 to be: Revenue was anticipated to grow by a high single digit percentage at CER and adjusted EBITA margin was anticipated to be in the mid-30s per cent of revenue. Sobi has now upgraded its full-year revenue outlook based on year-to-date performance and accelerated momentum in Q3. Group revenue grew 15 per cent at CER year-to-date and 21 per cent at...
PR Newswire
19/10/2025

PSMAddition data show Novartis Pluvicto™ delays progression to end-stage…

Pluvicto TMplus standard of care (ARPI + ADT) significantly reduced risk of progression or death by 28% (HR 0.72) versus SoC alone, with positive trend in OS (HR 0.84) in PSMA+ metastatic hormone-sensitive prostate cancer (mHSPC) 1 Most patients with mHSPC progress to metastatic castration-resistant prostate cancer, underscoring urgent need for new therapies that can reduce risk of progression in earlier disease settings 2 ,3 The safety profile and tolerability of...
Nasdaq GlobeNewswire
19/10/2025

Genmab Announces New Data Demonstrating Investigational Rinatabart Sesutecan…

Media Release COPENHAGEN, Denmark; October 18, 2025 Updated data from the Phase 1/2 RAINFOL™-01 trial showed rinatabart sesutecan (Rina-S®) 100 mg/m2 demonstrated 50% confirmed objective response rate (ORR), including two complete responses (CR), regardless of FRα expressionA Phase 3 trial in endometrial cancer is underwayU.S. FDA recently granted Breakthrough Therapy Designation to Rina-S for advanced endometrial cancer Genmab A/S (Nasdaq:GMAB) a...
Nasdaq GlobeNewswire
18/10/2025

Roche’s phase III evERA data showed giredestrant significantly improved…

Giredestrant plus everolimus reduced the risk of disease progression or death by 44% and 62% in ITT andESR1 -mutated populations, respectively, in a post-CDK inhibitor setting, compared with standard-of-care endocrine therapy plus everolimus 1 The giredestrant combination was well tolerated; no new safety signals were observed including no photopsia 1Overall survival data were immature, but a clear positive trend was seen in both the ITT andESR1 -mutated populations 1 If...
Nasdaq GlobeNewswire
18/10/2025

FDA approves Novo Nordisk's oral semaglutide for cardiovascular (CV) risk…

This new indication makes Rybelsus® the only oral GLP-1 medicine approved to reduce the risk of MACE in adults with type 2 diabetes who are at high risk for these events. It serves for both primary prevention (reducing the risk of major adverse cardiovascular events by preventing or managing risk factors in adults who are at high risk for these events) and secondary prevention (reducing the risk of another event in people who have had a serious CV event). This new indication makes Rybelsus ®...
PR Newswire
17/10/2025

Roche presents new phase III pivotal data for vamikibart in uveitic macular…

Vamikibart is the first non-steroid targeted therapy designed to address inflammation driving UME and may offer a potential new treatment option for patientsVision improvements were seen in both pivotal studies, achieving statistical significance in MEERKAT and nominal significance in SANDCATThe MEERKAT and SANDCAT trials are ongoing and the data will be discussed with health authorities globallyBasel, 17 October 2025 - Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today results...
Nasdaq GlobeNewswire
17/10/2025

Fagron’s share buy-back program: Weekly update

Regulated information Nazareth (Belgium)/Rotterdam (The Netherlands), 17 October 2025 – 6PM CET Fagron’s share buy-back program: Weekly update In the period from 16 October 2025 through 17 October 2025, Fagron purchased 20,000 of its owns shares at an average price of € 20.609 per share corresponding to a total amount of € 412,180.00. These purchases are part of the share buy-back program of up to 200,000 Fagron shares to fulfill Fagron’s obligations under its long-term incentive scheme,...
Nasdaq GlobeNewswire
17/10/2025

Oxurion Receives Amended Transparency Notifications from Atlas Special…

Oxurion Receives Amended Transparency Notifications from Atlas Special Opportunities II LLC Leuven, BELGIUM – October 17, 2025 – 06:00 PM CET - Oxurion NV (Euronext Brussels: OXUR), a company headquartered in Leuven, today announced that, pursuant to Belgian Transparency legislation1 it has received transparency notifications as follows: Oxurion…
Actusnews Wire
17/10/2025

RAMSAY SANTE : annual results at the end of June 2025

PRESS RELEASE Paris, 17 thOctober 2025 Annual results at the end of June 2025 Revenue growth of 4.7% and Group EBITDA up 1.7% despite reduction in public funding; secured long term financing frameworkActivity growth and cost control mitigate low French tariffs Group revenue increased by 4.7% to €5.2bn supported by activity volume growth and former Cosem primary care centres acquired in June 2024. Revenue growth of 2.7% on a like-for-like basis...
Nasdaq GlobeNewswire
17/10/2025

Zealand Pharma major shareholder announcement: Van Herk Investments B.V.

Company announcement – No. 22 / 2025 Zealand Pharma major shareholder announcement: Van Herk Investments B.V.Copenhagen, Denmark, October 17, 2025 –Zealand Pharma A/S (“Zealand”) (NASDAQ: ZEAL) (CVR-no. 20045078), a biotechnology company focused on the discovery and development of innovative peptide-based medicines, today reports receipt on 16 October 2025 of notification pursuant to Section 38 of the Danish Capital Markets Act from the following major shareholder:As of 15 October...
Nasdaq GlobeNewswire
17/10/2025

Wobble Genomics Presents Latest Data at ESMO: establishing the robustness of an…

The method identified novel isoforms of key cancer genes HER2 and TROP2 in patient blood samples, allowing more effective ADC development and more accurate patient stratification. The method identified novel isoforms of key cancer genes HER2 and TROP2 in patient blood samples, allowing more effective ADC development and more accurate patient stratification. Dr.Richard Kuo, Wobble Genomics CEO and Founder, said: "Our new platforms mark a major breakthrough in liquid biopsy technology,...
PR Newswire
17/10/2025

Sterile Dry Powder Active Pharmaceutical Ingredient (API) Market is expected to…

The global Sterile Dry Powder API Market is expanding due to the growing demand for aseptic pharmaceutical production and biologics. With major players investing in sterile manufacturing facilities, the market is set to see strong growth across key regions like North America, Europe, and Asia-Pacific. The global Sterile Dry Powder API Market is expanding due to the growing demand for aseptic pharmaceutical production and biologics. With major players investing in sterile manufacturing...
PR Newswire
17/10/2025

POP Treatment and Management / Pelvic Organ Prolapse Market worth $1.06 billion…

Browse in-depth TOC on "POP Treatment and Management / Pelvic Organ Prolapse Market" Browse in-depth TOC on "POP Treatment and Management / Pelvic Organ Prolapse Market" 345 - Tables 42 - Figures 331 - Pages By treatment,The POP Treatment and Management / Pelvic Organ Prolapse market is divided into two main segments based on treatment: surgical and non-surgical. Surgical treatment type is further divided into colpocleisis, colporrhapy, sacrocolpopexy, sacrohysteropexy…
PR Newswire
17/10/2025

Syngene International invests in dedicated peptide laboratory and advanced…

The dedicated peptide laboratory is designed to produce a wide range of molecules, including linear peptides, cyclic peptides, and peptide-drug conjugates, and supports synthesis scale-up to 800 mmol (millimole). With six automated peptide synthesizers operating in parallel and equipped with robotic arms, the lab reduces project timelines by weeks or even months while ensuring consistent results. It also features integrated Solid-Phase Peptide Synthesis (SPPS), High-Performance Liquid…
PR Newswire
17/10/2025

Boehringer’s zongertinib demonstrated a 77% objective response rate in…

/ Ridgefield, Connecticut, U.S. Data from the Phase Ib Beamion LUNG-1 trial evaluating zongertinib in treatment-naïve patients with advanced HER2 ( ERBB2 )-mutant NSCLC were presented for the first time at ESMO 2025. Confirmed response by blinded independent central review was 77%, with 96% of patients achieving disease control. 1 Zongertinib recently received Breakthrough Therapy Designations for first-line treatment by the U.S. FDA and China’s CDE. Boehringer Ingelheim reported...
Nasdaq GlobeNewswire
17/10/2025

Patient Experience Technology Market worth $1.16 billion by 2030 with 11.8% CAGR…

Browse in-depth TOC on "Patient Experience Technology Market" Browse in-depth TOC on "Patient Experience Technology Market" 150 - Tables 50 - Figures 350 - Pages By offerings,the patient experience technology market is segmented into software and services. The software segment is expected to dominate the patient experience technology market during the forecast period. The growth is driven by the increasing adoption of digital tools that enhance patient engagement and...
PR Newswire
17/10/2025

Natural Killer Cell Therapies Lead $254B Immunotherapy Market Transformation

VANCOUVER, BC, Oct. 17, 2025 /PRNewswire/ -- Equity InsiderNews Commentary – MIT and Harvardscientists recently created engineered CAR-NK cells that hide from the immune system and more effectively destroy cancer, opening doors to off-the-shelf treatments doctors can administer immediately after diagnosis instead of waiting weeks for personalized cell production[1]. Eight new oncology approvals between July and September 2025 demonstrate how cellular immunotherapy platforms are solving…
PR Newswire
17/10/2025

Precision Oncology Approaches Drive $312B Market Transformation

VANCOUVER, Oct. 17, 2025 /PRNewswire/ -- USA News Group News Commentary – Biomarker-driven drug development accelerates across oncology as companies advance novel mechanisms targeting previously difficult populations, with recent clinical data demonstrating high response rates in molecularly defined patient subgroups while FDA priority reviews compress development timelines for innovative platforms1. Multi-cancer early detection blood tests have correctly identify two thirds of cancers with a…
PR Newswire
17/10/2025
Altri  Comunicati